页面有问题?请点击打印板-》打印版                  [推荐此文给朋友]
[博讯主页]->[大陆新闻]
   

葛兰素史克(中国)公司就行贿事件正式向中国道歉
(博讯北京时间2014年9月19日 转载)
     国际在线消息:长沙市中级人民法院19日依法对葛兰素史克(中国)投资有限公司(简称GSKCI)和马克锐等人对非国家工作人员行贿、非国家工作人员受贿案进行审理。GSKCI被判处罚金人民币30亿元,这是迄今为止中国开出的最大罚单。
    
     对此,葛兰素史克总公司迅速发布了致歉声明,称总公司完全认同中国司法机关依法认定的事实和证据,服从中国司法机关的依法判决,并向中国患者、医生、医院和中国政府、全体中国人民深刻道歉,对于由此造成的损害,葛兰素史克总公司深感痛心和愧疚。对由于受到葛兰素史克中国公司非法调查而受到伤害的有关人员,葛兰素史克总公司也深表歉意。

    
    以下为声明全文:
    
    中国司法机关经过全面深入调查,依法认定葛兰素史克中国公司为谋取不正当利益,给予非国家工作人员财物,构成对非国家工作人员行贿罪。葛兰素史克总公司完全认同中国司法机关依法认定的事实和证据,服从中国司法机关的依法判决,并向中国患者、医生、医院和中国政府、全体中国人民深刻道歉,对于由此造成的损害,葛兰素史克总公司深感痛心和愧疚。对由于受到葛兰素史克中国公司非法调查而受到伤害的有关人员,葛兰素史克总公司也深表歉意。
    
    葛兰素史克中国公司的违法行为同样严重违背了葛兰素史克总公司的规章制度,完全背离了总公司要求员工遵守的价值观和行为准则。这些行为未能及时被发现并被制止,葛兰素史克总公司深感遗憾。葛兰素史克总公司已经深刻反省,并从中吸取教训,采取了具体措施,全面整改葛兰素史克中国公司运营中存在的问题,尽一切努力,重新赢得中国人民的信任。
    
    今天,葛兰素史克总公司进一步向中国政府和人民承诺,葛兰素史克中国公司将以实际行动在中国医药行业树立改革的样板:将坚持在中国持续投资,并一如既往地支持中国的科技发展;将针对流行于中国的疾病,进一步推进药物和疫苗的研发。葛兰素史克中国公司还将通过扩大生产、扩大药品价格下浮空间,让中国农村地区和城市一样,提高对葛兰素史克药品的可及性。
    
    葛兰素史克总公司将以践行这一系列长远的发展战略,致力于促进中国人民的健康福祉,为中国经济社会发展积极贡献力量。
    
    GSK plc Statement of Apology to the People of China
    
    Following a comprehensive investigation by the Chinese judicial authorities, GSK China Investment Co. Ltd (GSKCI) has been identified according to Chinese law to have offered money or property to non-government personnel in order to obtain improper commercial gains, and has been found guilty of bribing non-government personnel. GSK plc fully accepts the facts and evidence of the investigation, and the verdict of the Chinese judicial authorities. Furthermore, GSK plc sincerely apologises to the Chinese patients, doctors and hospitals, and to the Chinese Government and the Chinese people. GSK plc deeply regrets the damage caused. GSK plc also apologises for the harm caused to individuals who were illegally investigated by GSKCI.
    
    The illegal activities of GSKCI are a clear breach of GSK plc s governance and compliance procedures; and are wholly contrary to the values and standards we expect from our employees. It is deeply disappointing that these issues were not identified and addressed. GSK plc has reflected deeply and learned from its mistakes, has taken steps to comprehensively rectify the issues identified at the operations of GSKCI, and must work hard to regain the trust of the Chinese people.
    
    Today, GSK plc makes a further commitment to the Chinese government and people that GSKCI will take tangible actions to establish itself as a model for reform in China s healthcare industry: by continuing to invest in China and supporting China's scientific development; and by further development of innovative new medicines and vaccines for diseases prevalent in China. GSKCI will also increase access to its products in both city and rural areas of China through greater expansion of production and through price flexibility.
    
    This long-term development strategy of GSK plc will promote the future health and well-being of the Chinese people, and positively contribute to China s economic and social development. (博讯 boxun.com)
1951811
分享:
blog comments powered by Disqus
   
相关报道(更多请利用搜索功能):
·葛兰素史克中国公司被罚30亿元 数名被告被判刑 (图)
·葛兰素史克商业侦探出庭受审 (图)
·葛兰素史克私家侦探案开审 上海一中院微博直播 (图)
·中国将审理葛兰素史克私人调查案 或禁家属外交官旁听 (图)
·英媒:葛兰素史克让在华跨国公司听到警钟 (图)
·一波未平葛兰素史克又遭指控瞒税
·葛兰素史克15元药品来华卖207元 三成药费行贿
·中国医疗腐败 葛兰素史克或为替罪羊
·葛兰素史克3成药费为行贿 15元药来华卖207元 (图)
·葛兰素史克捞金术曝光:15元药品来华卖207元 (图)
·葛兰素史克因报销费违规开除中国雇员
·上海卫计委原副主任被逮捕 或涉葛兰素史克案
·面对巨额罚款 葛兰素史克威胁退出中国
·葛兰素史克高层默许在中国行贿年公关费上千万
·葛兰素史克在华行贿细节:10万元摆平北京工商
·葛兰素史克涉贿案追踪:既行贿又受贿 明禁暗许
·葛兰素史克编织合规外衣销售政策鼓励以身试法
·葛兰素史克案 显示中共权利斗争已无法掩饰
·媒体曝胡耀邦之女发声明否认涉葛兰素史克案
·何清涟:调查葛兰素史克的醉翁之意
·马未都:葛兰素史克在华行贿曝药价黑幕
联系我们


All rights reserved
博讯是畅所欲言的场所、所有文章均不一定代表博讯立场
声明:博讯由编辑、义务留学生、学者维护,如有版权问题,请联系我们。另外,欢迎其他媒体 转载博讯文章,为尊重作者的辛勤劳动以及所承担风险,尊重博讯广大义务人士的奉献,请转载时注明来源和作者。